Forest Gets Untitled Letter After Reps Tout Weight Loss Adverse Event as Potentially Beneficial

Drug Industry Daily
A A
Forest Laboratories has been hit with an untitled letter after two of its sales reps implied that weight loss while using Daliresp tablets — listed as an adverse reaction — could be beneficial for overweight chronic obstructive pulmonary disease (COPD) patients.

To View This Article:

Login

Subscribe To Drug Industry Daily